drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01174 | DB09075 | 697 | 498 | [
"DDInter1442",
"DDInter621"
] | Phenobarbital | Edoxaban | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy. | Moderate | 1 | [
[
[
697,
24,
498
]
],
[
[
697,
63,
222
],
[
222,
24,
498
]
],
[
[
697,
25,
1017
],
[
1017,
63,
498
]
],
[
[
697,
24,
129
],
[
129,
2... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital (Compound) resembles Primidone (Compound) and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Phenobarbital may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Edoxaban
Phenobarbital may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban |
DB01041 | DB01178 | 770 | 369 | [
"DDInter1789",
"DDInter357"
] | Thalidomide | Chlormezanone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Moderate | 1 | [
[
[
770,
24,
369
]
],
[
[
770,
25,
1532
],
[
1532,
63,
369
]
],
[
[
770,
24,
272
],
[
272,
24,
369
]
],
[
[
770,
63,
13
],
[
13,
24,... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
],
[
"Ifosf... | Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Chlormezanone
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Chlormezanone (Compound) |
DB00831 | DB01211 | 1,178 | 609 | [
"DDInter1866",
"DDInter393"
] | Trifluoperazine | Clarithromycin | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
1178,
24,
609
]
],
[
[
1178,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1178,
7,
5727
],
[
5727,
46,
609
]
],
[
[
1178,
18,
20003
],
[
20003,... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} ... | Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Trifluoperazine (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Clarithromycin (Compound)
Trifluoperazine (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Clarithromycin (Compound)
Trifluoperazine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00420 | DB00748 | 508 | 662 | [
"DDInter1532",
"DDInter297"
] | Promazine | Carbinoxamine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Moderate | 1 | [
[
[
508,
24,
662
]
],
[
[
508,
24,
28
],
[
28,
40,
662
]
],
[
[
508,
1,
11786
],
[
11786,
40,
662
]
],
[
[
508,
63,
1594
],
[
1594,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Promazine (Compound) resembles Captodiame (Compound) and Captodiame (Compound) resembles Carbinoxamine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Promazine (Compound) resembles Chlorpromazine (Compound) and Chlor
Promazine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Carbinoxamine (Compound)
Promazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Promazine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Carbinoxamine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Promazine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine |
DB00927 | DB12267 | 1,559 | 1,476 | [
"DDInter712",
"DDInter233"
] | Famotidine | Brigatinib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1559,
24,
1476
]
],
[
[
1559,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1559,
24,
918
],
[
918,
24,
1476
]
],
[
[
1559,
63,
79
],
[
79,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Famotidine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Brigatinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Brigatinib
Famotidine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Brigatinib |
DB00108 | DB00495 | 1,066 | 139 | [
"DDInter1268",
"DDInter1961"
] | Natalizumab | Zidovudine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | Major | 2 | [
[
[
1066,
25,
139
]
],
[
[
1066,
25,
1083
],
[
1083,
24,
139
]
],
[
[
1066,
25,
309
],
[
309,
63,
139
]
],
[
[
1066,
64,
669
],
[
669,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
... | Natalizumab may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Denileukin diftitox and Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine (Compound) resembles Zidovudine (Compound) and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Natalizumab may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Idoxuridine (Compound) and Idoxuridine (Compound) resembles Zidovudine (Compound) |
DB00041 | DB01452 | 1,648 | 993 | [
"DDInter38",
"DDInter532"
] | Aldesleukin | Diamorphine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. | Moderate | 1 | [
[
[
1648,
24,
993
]
],
[
[
1648,
24,
421
],
[
421,
40,
993
]
],
[
[
1648,
24,
475
],
[
475,
25,
993
]
],
[
[
1648,
25,
770
],
[
770,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Diamorphine
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Diamorphine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound) |
DB05239 | DB15091 | 866 | 676 | [
"DDInter425",
"DDInter1901"
] | Cobimetinib | Upadacitinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
866,
25,
676
]
],
[
[
866,
24,
1430
],
[
1430,
24,
676
]
],
[
[
866,
64,
1249
],
[
1249,
24,
676
]
],
[
[
866,
25,
283
],
[
283,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may lead to a major life threatening interaction when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Cobimetinib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may lead to a major life threatening interaction when taken with Upadacitinib
Cobimetinib may lead to a major life threatening interaction when taken with Boceprevir and Boceprevir may lead to a major life threatening interaction when taken with Upadacitinib |
DB01058 | DB12887 | 978 | 1,598 | [
"DDInter1510",
"DDInter1750"
] | Praziquantel | Tazemetostat | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030.[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
978,
24,
1598
]
],
[
[
978,
24,
1476
],
[
1476,
24,
1598
]
],
[
[
978,
62,
752
],
[
752,
24,
1598
]
],
[
[
978,
63,
1324
],
[
1324,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Praziquantel may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Tazemetostat
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may lead to a major life threatening interaction when taken with Tazemetostat
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat |
DB00015 | DB06441 | 582 | 936 | [
"DDInter1585",
"DDInter283"
] | Reteplase | Cangrelor | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. | Major | 2 | [
[
[
582,
25,
936
]
],
[
[
582,
23,
1631
],
[
1631,
62,
936
]
],
[
[
582,
24,
97
],
[
97,
24,
936
]
],
[
[
582,
24,
643
],
[
643,
63,... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Reteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Cangrelor
Reteplase may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Cangrelor
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Cangrelor
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Cangrelor
Reteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Cangrelor
Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor |
DB00434 | DB00902 | 13 | 104 | [
"DDInter459",
"DDInter1168"
] | Cyproheptadine | Methdilazine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
13,
24,
104
]
],
[
[
13,
40,
11286
],
[
11286,
1,
104
]
],
[
[
13,
24,
820
],
[
820,
1,
104
]
],
[
[
13,
24,
537
],
[
537,
40,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{... | Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Methdilazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Cyproheptadine (Compound) resembles Metixene (Compound) and Metixene (Compound) resembles Methdilazine (Compound)
Cyproheptadine (Compound) resembles Mianserin (Compound) and Mianserin (Compound) resembles Methdilazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Cyproheptadine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Methdilazine (Compound) |
DB00030 | DB00831 | 1,685 | 1,178 | [
"DDInter934",
"DDInter1866"
] | Insulin human | Trifluoperazine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
1685,
24,
1178
]
],
[
[
1685,
24,
695
],
[
695,
40,
1178
]
],
[
[
1685,
24,
1630
],
[
1630,
1,
1178
]
],
[
[
1685,
24,
417
],
[
417,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
]... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trifluoperazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Trifluoperazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Insulin human may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Trifluoperazine
Insulin human may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Trifluoperazine |
DB08865 | DB12364 | 1,593 | 1,421 | [
"DDInter448",
"DDInter200"
] | Crizotinib | Betrixaban | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
1593,
24,
1421
]
],
[
[
1593,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
1593,
24,
992
],
[
992,
24,
1421
]
],
[
[
1593,
63,
529
],
[
529,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir... | Crizotinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ginger and Ginger may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Crizotinib may lead to a major life threatening interaction when taken with Telithromycin and Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Crizotinib may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Betrixaban |
DB00647 | DB11130 | 675 | 407 | [
"DDInter528",
"DDInter1344"
] | Dextropropoxyphene | Opium | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Major | 2 | [
[
[
675,
25,
407
]
],
[
[
675,
25,
662
],
[
662,
24,
407
]
],
[
[
675,
24,
1054
],
[
1054,
24,
407
]
],
[
[
675,
40,
576
],
[
576,
2... | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxami... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Kaolin and Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene may lead to a major life threatening interaction when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene (Compound) resembles Doxylamine (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Opium
Dextropropoxyphene (Compound) resembles Clidinium (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00673 | DB12825 | 723 | 1,375 | [
"DDInter112",
"DDInter1032"
] | Aprepitant | Lefamulin | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
723,
24,
1375
]
],
[
[
723,
24,
159
],
[
159,
63,
1375
]
],
[
[
723,
24,
1532
],
[
1532,
24,
1375
]
],
[
[
723,
62,
1101
],
[
1101,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may lead to a major life threatening interaction when taken with Sonidegib and Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
Aprepitant may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Lefamulin
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Lefamulin |
DB00005 | DB11767 | 1,057 | 1,583 | [
"DDInter687",
"DDInter1643"
] | Etanercept | Sarilumab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Major | 2 | [
[
[
1057,
25,
1583
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
1583
]
],
[
[
1057,
24,
362
],
[
362,
24,
1583
]
],
[
[
1057,
25,
850
],
[
850,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Etanercept may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Etanercept may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Etanercept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sarilumab
Etanercept may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Sarilumab
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab |
DB01050 | DB01244 | 848 | 762 | [
"DDInter900",
"DDInter192"
] | Ibuprofen | Bepridil | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). | Moderate | 1 | [
[
[
848,
24,
762
]
],
[
[
848,
6,
4973
],
[
4973,
45,
762
]
],
[
[
848,
21,
28698
],
[
28698,
60,
762
]
],
[
[
848,
24,
1478
],
[
1478,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ibuprofen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bepridil (Compound)
Ibuprofen (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Bepridil (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen (Compound) resembles Procarbazine (Compound) and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Bepridil |
DB00851 | DB05679 | 611 | 1,683 | [
"DDInter463",
"DDInter1907"
] | Dacarbazine | Ustekinumab | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
611,
24,
1683
]
],
[
[
611,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
611,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
611,
63,
305
],
[
305,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Dacarbazine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Dacarbazine may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Ustekinumab
Dacarbazine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab
Dacarbazine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ustekinumab |
DB00373 | DB11963 | 461 | 1,045 | [
"DDInter1809",
"DDInter465"
] | Timolol | Dacomitinib | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed. | Moderate | 1 | [
[
[
461,
24,
1045
]
],
[
[
461,
24,
1376
],
[
1376,
24,
1045
]
],
[
[
461,
24,
1670
],
[
1670,
25,
1045
]
],
[
[
461,
24,
1376
],
[
1376,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Timolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Timolol (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib |
DB00575 | DB01309 | 1,020 | 1,254 | [
"DDInter412",
"DDInter933"
] | Clonidine | Insulin glulisine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
1020,
24,
1254
]
],
[
[
1020,
24,
274
],
[
274,
23,
1254
]
],
[
[
1020,
24,
167
],
[
167,
24,
1254
]
],
[
[
1020,
24,
1450
],
[
1450,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine |
DB00615 | DB08820 | 690 | 1,478 | [
"DDInter1589",
"DDInter997"
] | Rifabutin | Ivacaftor | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Major | 2 | [
[
[
690,
25,
1478
]
],
[
[
690,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
690,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
690,
24,
1135
],
[
1135,... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Rifabutin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Rifabutin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Rifabutin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor |
DB01124 | DB09381 | 1,411 | 192 | [
"DDInter1828",
"DDInter678"
] | Tolbutamide | Esterified estrogens | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis. | Moderate | 1 | [
[
[
1411,
24,
192
]
],
[
[
1411,
63,
752
],
[
752,
23,
192
]
],
[
[
1411,
24,
1264
],
[
1264,
23,
192
]
],
[
[
1411,
24,
1019
],
[
1019,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens |
DB09263 | DB14520 | 1,436 | 1,229 | [
"DDInter1399",
"DDInter1785"
] | Patiromer | Tetraferric tricitrate decahydrate | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1436,
24,
1229
]
],
[
[
1436,
63,
542
],
[
542,
24,
1229
]
],
[
[
1436,
63,
542
],
[
542,
24,
954
],
[
954,
24,
1229
]
],
[
[
1436,
... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levot... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous and Calcium glubionate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Tetraferric tricitrate decahydrate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous and Calcium glubionate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil and Baloxavir marboxil may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate |
DB00795 | DB05260 | 50 | 1,329 | [
"DDInter1725",
"DDInter804"
] | Sulfasalazine | Gallium nitrate | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | Gallium nitrate is a nitrate salt of , a heavy metal that has been used as a diagnostic agent. Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness. Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours. | Moderate | 1 | [
[
[
50,
24,
1329
]
],
[
[
50,
63,
1555
],
[
1555,
24,
1329
]
],
[
[
50,
40,
712
],
[
712,
24,
1329
]
],
[
[
50,
24,
123
],
[
123,
24... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Sulfasalazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Gallium nitrate
Sulfasalazine may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Gallium nitrate
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may lead to a major life threatening interaction when taken with Gallium nitrate
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may lead to a major life threatening interaction when taken with Gallium nitrate
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate |
DB00938 | DB04844 | 455 | 843 | [
"DDInter1635",
"DDInter1778"
] | Salmeterol | Tetrabenazine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
455,
24,
843
]
],
[
[
455,
21,
28698
],
[
28698,
60,
843
]
],
[
[
455,
63,
1555
],
[
1555,
24,
843
]
],
[
[
455,
24,
823
],
[
823,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is cau... | Salmeterol (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Salmeterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Salmeterol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Tetrabenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Tetrabenazine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Tetrabenazine |
DB01004 | DB11767 | 563 | 1,583 | [
"DDInter806",
"DDInter1643"
] | Ganciclovir | Sarilumab | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Moderate | 1 | [
[
[
563,
24,
1583
]
],
[
[
563,
24,
850
],
[
850,
24,
1583
]
],
[
[
563,
1,
248
],
[
248,
24,
1583
]
],
[
[
563,
63,
372
],
[
372,
2... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Ganciclovir may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sarilumab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Sarilumab
Ganciclovir may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Sarilumab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Sarilumab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may lead to a major life threatening interaction when taken with Sarilumab |
DB00835 | DB04948 | 100 | 1,084 | [
"DDInter245",
"DDInter1083"
] | Brompheniramine | Lofexidine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Moderate | 1 | [
[
[
100,
24,
1084
]
],
[
[
100,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
100,
63,
1020
],
[
1020,
1,
1084
]
],
[
[
100,
24,
1311
],
[
1311,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Lofexidine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine (Compound) resembles Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine (Compound) resembles Diphenhydramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine |
DB00816 | DB01221 | 1,674 | 1,190 | [
"DDInter1346",
"DDInter1007"
] | Orciprenaline | Ketamine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes. | Moderate | 1 | [
[
[
1674,
24,
1190
]
],
[
[
1674,
21,
28642
],
[
28642,
60,
1190
]
],
[
[
1674,
24,
222
],
[
222,
24,
1190
]
],
[
[
1674,
63,
73
],
[
73,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused b... | Orciprenaline (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Ketamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound) |
DB00903 | DB01067 | 1,680 | 959 | [
"DDInter686",
"DDInter826"
] | Etacrynic acid | Glipizide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
1680,
24,
959
]
],
[
[
1680,
63,
245
],
[
245,
40,
959
]
],
[
[
1680,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1680,
18,
1918
],
[
1918,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Etacrynic acid (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Glipizide (Compound)
Etacrynic acid (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is downregulated by Glipizide (Compound)
Etacrynic acid (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Glipizide (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00745 | DB11979 | 307 | 1,320 | [
"DDInter1236",
"DDInter625"
] | Modafinil | Elagolix | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
307,
24,
1320
]
],
[
[
307,
62,
168
],
[
168,
23,
1320
]
],
[
[
307,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
307,
63,
79
],
[
79,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"B... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may cause a minor interaction that can limit clinical effects when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Modafinil (Compound) resembles Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix |
DB00515 | DB00798 | 589 | 1,132 | [
"DDInter387",
"DDInter815"
] | Cisplatin | Gentamicin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use. | Moderate | 1 | [
[
[
589,
24,
1132
]
],
[
[
589,
21,
28751
],
[
28751,
60,
1132
]
],
[
[
589,
24,
361
],
[
361,
63,
1132
]
],
[
[
589,
63,
837
],
[
837,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caus... | Cisplatin (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Gentamicin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cisplatin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin and Human botulinum neurotoxin A/B immune globulin may lead to a major life threatening interaction when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may lead to a major life threatening interaction when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Capreomycin and Capreomycin may lead to a major life threatening interaction when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Gentamicin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin |
DB01041 | DB11823 | 770 | 858 | [
"DDInter1789",
"DDInter673"
] | Thalidomide | Esketamine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect. | Moderate | 1 | [
[
[
770,
24,
858
]
],
[
[
770,
24,
272
],
[
272,
24,
858
]
],
[
[
770,
63,
506
],
[
506,
24,
858
]
],
[
[
770,
25,
1532
],
[
1532,
2... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Chlorpheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine |
DB00774 | DB01249 | 1,577 | 258 | [
"DDInter889",
"DDInter958"
] | Hydroflumethiazide | Iodixanol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
1577,
24,
258
]
],
[
[
1577,
24,
497
],
[
497,
1,
258
]
],
[
[
1577,
21,
28748
],
[
28748,
60,
258
]
],
[
[
1577,
40,
178
],
[
178,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Hydroflumethiazide (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Iodixanol (Compound)
Hydroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Hydroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Iodixanol
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Iodixanol
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) upregulates BAMBI (Gene) and BAMBI (Gene) is upregulated by Iodixanol (Compound) |
DB00795 | DB01099 | 50 | 1,272 | [
"DDInter1725",
"DDInter744"
] | Sulfasalazine | Flucytosine | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
50,
24,
1272
]
],
[
[
50,
63,
485
],
[
485,
24,
1272
]
],
[
[
50,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
50,
24,
445
],
[
445,
63... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine (Compound) downregulates COPB2 (Gene) and COPB2 (Gene) is upregulated by Flucytosine (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Flucytosine (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran and Givosiran may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine |
DB00533 | DB06228 | 1,416 | 792 | [
"DDInter1613",
"DDInter1609"
] | Rofecoxib | Rivaroxaban | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2 | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Moderate | 1 | [
[
[
1416,
24,
792
]
],
[
[
1416,
24,
1220
],
[
1220,
24,
792
]
],
[
[
1416,
24,
298
],
[
298,
63,
792
]
],
[
[
1416,
63,
305
],
[
305,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban |
DB09065 | DB09272 | 760 | 412 | [
"DDInter424",
"DDInter632"
] | Cobicistat | Eluxadoline | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Major | 2 | [
[
[
760,
25,
412
]
],
[
[
760,
24,
791
],
[
791,
63,
412
]
],
[
[
760,
64,
1131
],
[
1131,
24,
412
]
],
[
[
760,
63,
700
],
[
700,
2... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eluxadoline"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxilaprevir"
],
[
"Voxilap... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir and Voxilaprevir may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may lead to a major life threatening interaction when taken with Methysergide and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may lead to a major life threatening interaction when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Eluxadoline |
DB00402 | DB00748 | 1,407 | 662 | [
"DDInter685",
"DDInter297"
] | Eszopiclone | Carbinoxamine | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Moderate | 1 | [
[
[
1407,
24,
662
]
],
[
[
1407,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1407,
24,
128
],
[
128,
24,
662
]
],
[
[
1407,
6,
6017
],
[
6017,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Eszopiclone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Eszopiclone (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Carbinoxamine (Compound)
Eszopiclone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Carbinoxamine (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Eszopiclone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine |
DB01362 | DB14509 | 497 | 1,399 | [
"DDInter960",
"DDInter1081"
] | Iohexol | Lithium carbonate | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
497,
25,
1399
]
],
[
[
497,
64,
589
],
[
589,
23,
1399
]
],
[
[
497,
24,
1574
],
[
1574,
23,
1399
]
],
[
[
497,
64,
820
],
[
820,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} ma... | Iohexol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iohexol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iohexol may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iohexol may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Lithium carbonate
Iohexol (Compound) resembles Iodixanol (Compound) and Iodixanol may lead to a major life threatening interaction when taken with Lithium carbonate
Iohexol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate |
DB09330 | DB11799 | 985 | 627 | [
"DDInter1352",
"DDInter205"
] | Osimertinib | Bictegravir | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
985,
24,
627
]
],
[
[
985,
63,
1362
],
[
1362,
24,
627
]
],
[
[
985,
64,
478
],
[
478,
24,
627
]
],
[
[
985,
24,
466
],
[
466,
6... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Osimertinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Osimertinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Osimertinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Osimertinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bictegravir
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may lead to a major life threatening interaction when taken with Bictegravir
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Bictegravir
Osimertinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Bictegravir |
DB01060 | DB13179 | 319 | 68 | [
"DDInter83",
"DDInter1882"
] | Amoxicillin | Troleandomycin | Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. | A macrolide antibiotic that is similar to erythromycin. | Minor | 0 | [
[
[
319,
23,
68
]
],
[
[
319,
24,
1662
],
[
1662,
24,
68
]
],
[
[
319,
64,
663
],
[
663,
24,
68
]
],
[
[
319,
63,
1096
],
[
1096,
24... | [
[
[
"Amoxicillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
]
],
[
[
"Amoxicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
... | Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Amoxicillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Troleandomycin
Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Amoxicillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Amoxicillin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Loratadine (Compound) and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin |
DB01072 | DB01410 | 915 | 423 | [
"DDInter129",
"DDInter375"
] | Atazanavir | Ciclesonide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Moderate | 1 | [
[
[
915,
24,
423
]
],
[
[
915,
63,
1573
],
[
1573,
1,
423
]
],
[
[
915,
63,
1351
],
[
1351,
40,
423
]
],
[
[
915,
64,
1486
],
[
1486,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ciclesonide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Ciclesonide (Compound)
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Ciclesonide (Compound)
Atazanavir may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Ciclesonide (Compound)
Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ciclesonide (Compound)
Atazanavir (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Ciclesonide (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Ciclesonide
Atazanavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Ciclesonide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide |
DB00472 | DB09272 | 758 | 412 | [
"DDInter758",
"DDInter632"
] | Fluoxetine | Eluxadoline | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
758,
24,
412
]
],
[
[
758,
63,
1594
],
[
1594,
24,
412
]
],
[
[
758,
24,
543
],
[
543,
24,
412
]
],
[
[
758,
25,
1347
],
[
1347,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Eluxadoline
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline |
DB01191 | DB14006 | 1,039 | 972 | [
"DDInter518",
"DDInter370"
] | Dexfenfluramine | Choline salicylate | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling. Choline salicylate is effective in the treatment of gout, rheumatic fever, rheumatoid arthritis and muscle injuries . This drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population . The UK government has regulated its use, due to toxicity in those under 16 years of age. Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers . | Moderate | 1 | [
[
[
1039,
24,
972
]
],
[
[
1039,
63,
553
],
[
553,
24,
972
]
],
[
[
1039,
24,
885
],
[
885,
24,
972
]
],
[
[
1039,
64,
222
],
[
222,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondapari... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate |
DB00978 | DB00983 | 739 | 480 | [
"DDInter1084",
"DDInter776"
] | Lomefloxacin | Formoterol | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989] | Moderate | 1 | [
[
[
739,
24,
480
]
],
[
[
739,
24,
1148
],
[
1148,
63,
480
]
],
[
[
739,
21,
28963
],
[
28963,
60,
480
]
],
[
[
739,
64,
870
],
[
870,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Lomefloxacin (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Formoterol (Compound)
Lomefloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Formoterol
Lomefloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Formoterol
Lomefloxacin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Lomefloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol |
DB00627 | DB01097 | 265 | 1,377 | [
"DDInter1286",
"DDInter1033"
] | Niacin | Leflunomide | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
265,
25,
1377
]
],
[
[
265,
7,
9489
],
[
9489,
46,
1377
]
],
[
[
265,
21,
29405
],
[
29405,
60,
1377
]
],
[
[
265,
24,
959
],
[
959,
... | [
[
[
"Niacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Niacin",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Leflun... | Niacin (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Leflunomide (Compound)
Niacin (Compound) causes Raised liver function tests (Side Effect) and Raised liver function tests (Side Effect) is caused by Leflunomide (Compound)
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide
Niacin may lead to a major life threatening interaction when taken with Rosuvastatin and Rosuvastatin may lead to a major life threatening interaction when taken with Leflunomide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Leflunomide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may lead to a major life threatening interaction when taken with Leflunomide |
DB00436 | DB09156 | 323 | 777 | [
"DDInter179",
"DDInter964"
] | Bendroflumethiazide | Iopromide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can cause several serious adverse effects, including cardiac events, thromboembolism, hypersensitivity reaction, and even death if administered intrathecally inadvertently, it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events. Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and orthography.[L46906,L46911] | Moderate | 1 | [
[
[
323,
24,
777
]
],
[
[
323,
63,
1648
],
[
1648,
24,
777
]
],
[
[
323,
40,
674
],
[
674,
24,
777
]
],
[
[
323,
24,
1512
],
[
1512,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleuki... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iopromide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life threatening interaction when taken with Iopromide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Bendroflumethiazide (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide |
DB00418 | DB06603 | 536 | 39 | [
"DDInter1650",
"DDInter1387"
] | Secobarbital | Panobinostat | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Moderate | 1 | [
[
[
536,
24,
39
]
],
[
[
536,
24,
112
],
[
112,
23,
39
]
],
[
[
536,
24,
272
],
[
272,
24,
39
]
],
[
[
536,
24,
578
],
[
578,
63,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat |
DB00014 | DB00726 | 521 | 1,164 | [
"DDInter839",
"DDInter1876"
] | Goserelin | Trimipramine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
521,
24,
1164
]
],
[
[
521,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
521,
25,
576
],
[
576,
40,
1164
]
],
[
[
521,
21,
28809
],
[
28809,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Goserelin may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Trimipramine (Compound)
Goserelin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Trimipramine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Trimipramine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Goserelin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Trimipramine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Trimipramine |
DB00675 | DB00834 | 888 | 932 | [
"DDInter1744",
"DDInter1215"
] | Tamoxifen | Mifepristone | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Major | 2 | [
[
[
888,
25,
932
]
],
[
[
888,
6,
7524
],
[
7524,
45,
932
]
],
[
[
888,
7,
1700
],
[
1700,
46,
932
]
],
[
[
888,
18,
4071
],
[
4071,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Mifepri... | Tamoxifen (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Tamoxifen (Compound) upregulates SIRT3 (Gene) and SIRT3 (Gene) is upregulated by Mifepristone (Compound)
Tamoxifen (Compound) downregulates PNP (Gene) and PNP (Gene) is downregulated by Mifepristone (Compound)
Tamoxifen (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Mifepristone (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mifepristone
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone |
DB00023 | DB06186 | 305 | 1,439 | [
"DDInter127",
"DDInter969"
] | Asparaginase Escherichia coli | Ipilimumab | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Moderate | 1 | [
[
[
305,
24,
1439
]
],
[
[
305,
24,
617
],
[
617,
24,
1439
]
],
[
[
305,
63,
268
],
[
268,
24,
1439
]
],
[
[
305,
24,
1627
],
[
1627,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Ipilimumab
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Ipilimumab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Ipilimumab |
DB00814 | DB14723 | 1,171 | 159 | [
"DDInter1143",
"DDInter1026"
] | Meloxicam | Larotrectinib | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201] | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
1171,
24,
159
]
],
[
[
1171,
24,
222
],
[
222,
23,
159
]
],
[
[
1171,
24,
98
],
[
98,
24,
159
]
],
[
[
1171,
63,
267
],
[
267,
2... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Meloxicam may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Meloxicam may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Meloxicam may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Larotrectinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB00959 | DB13139 | 1,486 | 1,032 | [
"DDInter1191",
"DDInter1063"
] | Methylprednisolone | Levosalbutamol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). | Minor | 0 | [
[
[
1486,
23,
1032
]
],
[
[
1486,
40,
1573
],
[
1573,
23,
1032
]
],
[
[
1486,
1,
617
],
[
617,
23,
1032
]
],
[
[
1486,
24,
1213
],
[
1213,... | [
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} m... | Methylprednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Methylprednisolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylprednisolone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Methylprednisolone (Compound) resembles Prednisone (Compound) and Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol |
DB00230 | DB00341 | 784 | 1,242 | [
"DDInter1516",
"DDInter343"
] | Pregabalin | Cetirizine | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders. | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects . Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects . | Moderate | 1 | [
[
[
784,
24,
1242
]
],
[
[
784,
24,
537
],
[
537,
63,
1242
]
],
[
[
784,
21,
29323
],
[
29323,
60,
1242
]
],
[
[
784,
25,
475
],
[
475,
... | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pregabalin (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Cetirizine (Compound)
Pregabalin may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Ifenprodil (Compound) and Ifenprodil (Compound) resembles Cetirizine (Compound)
Pregabalin (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pregabalin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Pregabalin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Fexofenadine (Compound) and Fexofenadine (Compound) resembles Cetirizine (Compound)
Pregabalin (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Cetirizine (Compound) |
DB00631 | DB01048 | 372 | 764 | [
"DDInter405",
"DDInter1"
] | Clofarabine | Abacavir | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir. | Moderate | 1 | [
[
[
372,
24,
764
]
],
[
[
372,
1,
325
],
[
325,
40,
764
]
],
[
[
372,
64,
1064
],
[
1064,
24,
764
]
],
[
[
372,
21,
28759
],
[
28759,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abacavir"
]
],
[
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Nelarabine"
],
[
"Nelarabine",
"{u} (Compound) resemble... | Clofarabine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Abacavir (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Clofarabine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Abacavir (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Clofarabine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Abacavir
Clofarabine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Cladribine (Compound) and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Clofarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Abacavir (Compound) |
DB01452 | DB06691 | 993 | 849 | [
"DDInter532",
"DDInter1155"
] | Diamorphine | Mepyramine | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
993,
24,
849
]
],
[
[
993,
63,
1594
],
[
1594,
24,
849
]
],
[
[
993,
24,
407
],
[
407,
63,
849
]
],
[
[
993,
64,
475
],
[
475,
2... | [
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB06209 | DB11095 | 256 | 235 | [
"DDInter1508",
"DDInter505"
] | Prasugrel | Desirudin | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing. | Major | 2 | [
[
[
256,
25,
235
]
],
[
[
256,
23,
297
],
[
297,
23,
235
]
],
[
[
256,
63,
1100
],
[
1100,
24,
235
]
],
[
[
256,
24,
1004
],
[
1004,
... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} m... | Prasugrel may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Desirudin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prasugrel may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Desirudin
Prasugrel may lead to a major life threatening interaction when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Desirudin
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Desirudin
Prasugrel may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Desirudin
Prasugrel (Compound) resembles Clopidogrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Desirudin |
DB01211 | DB06772 | 609 | 310 | [
"DDInter393",
"DDInter259"
] | Clarithromycin | Cabazitaxel | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
609,
24,
310
]
],
[
[
609,
24,
973
],
[
973,
24,
310
]
],
[
[
609,
6,
7524
],
[
7524,
45,
310
]
],
[
[
609,
21,
28692
],
[
28692,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clarithromycin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Clarithromycin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cabazitaxel (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clarithromycin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB00539 | DB08864 | 11 | 786 | [
"DDInter1837",
"DDInter1595"
] | Toremifene | Rilpivirine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. | Major | 2 | [
[
[
11,
25,
786
]
],
[
[
11,
24,
655
],
[
655,
1,
786
]
],
[
[
11,
6,
8374
],
[
8374,
45,
786
]
],
[
[
11,
21,
28698
],
[
28698,
60,... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirin... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Toremifene (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Rilpivirine (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Toremifene may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Toremifene may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Toremifene may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine |
DB01132 | DB14840 | 1,130 | 861 | [
"DDInter1472",
"DDInter1601"
] | Pioglitazone | Ripretinib | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglit | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors. | Moderate | 1 | [
[
[
1130,
24,
861
]
],
[
[
1130,
24,
351
],
[
351,
24,
861
]
],
[
[
1130,
62,
1051
],
[
1051,
24,
861
]
],
[
[
1130,
63,
1101
],
[
1101,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib |
DB00445 | DB06688 | 322 | 1,430 | [
"DDInter655",
"DDInter1677"
] | Epirubicin | Sipuleucel-T | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. | Moderate | 1 | [
[
[
322,
24,
1430
]
],
[
[
322,
35,
51
],
[
51,
24,
1430
]
],
[
[
322,
24,
869
],
[
869,
24,
1430
]
],
[
[
322,
25,
676
],
[
676,
63... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken... | Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Epirubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T |
DB00734 | DB01278 | 1,664 | 1,021 | [
"DDInter1605",
"DDInter1506"
] | Risperidone | Pramlintide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1664,
24,
1021
]
],
[
[
1664,
24,
1507
],
[
1507,
24,
1021
]
],
[
[
1664,
63,
1144
],
[
1144,
24,
1021
]
],
[
[
1664,
1,
519
],
[
519,... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone (Compound) resembles Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
DB00529 | DB01064 | 789 | 1,148 | [
"DDInter779",
"DDInter987"
] | Foscarnet | Isoprenaline | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Moderate | 1 | [
[
[
789,
24,
1148
]
],
[
[
789,
24,
480
],
[
480,
24,
1148
]
],
[
[
789,
21,
28717
],
[
28717,
60,
1148
]
],
[
[
789,
63,
251
],
[
251,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Foscarnet (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Isoprenaline (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Foscarnet may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Foscarnet may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline |
DB00701 | DB01067 | 1,091 | 959 | [
"DDInter90",
"DDInter826"
] | Amprenavir | Glipizide | Amprenavir is a protease inhibitor used to treat HIV infection. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
1091,
24,
959
]
],
[
[
1091,
63,
245
],
[
245,
40,
959
]
],
[
[
1091,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1091,
6,
8374
],
[
8374,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Amprenavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Glipizide (Compound)
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Glipizide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glipizide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Amprenavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00850 | DB01181 | 1,630 | 1,532 | [
"DDInter1432",
"DDInter906"
] | Perphenazine | Ifosfamide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1630,
24,
1532
]
],
[
[
1630,
6,
3486
],
[
3486,
45,
1532
]
],
[
[
1630,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
1630,
63,
1648
],
[
1... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compoun... | Perphenazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ifosfamide (Compound)
Perphenazine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine (Compound) resembles Promethazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide |
DB01023 | DB11967 | 409 | 710 | [
"DDInter716",
"DDInter210"
] | Felodipine | Binimetinib | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
409,
24,
710
]
],
[
[
409,
24,
1593
],
[
1593,
24,
710
]
],
[
[
409,
1,
336
],
[
336,
24,
710
]
],
[
[
409,
24,
1619
],
[
1619,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Felodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib |
DB00059 | DB01309 | 1,560 | 1,254 | [
"DDInter1404",
"DDInter933"
] | Pegaspargase | Insulin glulisine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
1560,
24,
1254
]
],
[
[
1560,
24,
1632
],
[
1632,
63,
1254
]
],
[
[
1560,
24,
1669
],
[
1669,
24,
1254
]
],
[
[
1560,
25,
695
],
[
695... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicotinamide"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide and Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide and Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine |
DB00227 | DB01073 | 1,463 | 1,488 | [
"DDInter1098",
"DDInter745"
] | Lovastatin | Fludarabine | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1463,
24,
1488
]
],
[
[
1463,
24,
372
],
[
372,
1,
1488
]
],
[
[
1463,
21,
28701
],
[
28701,
60,
1488
]
],
[
[
1463,
24,
36
],
[
36,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Lovastatin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound)
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin (Compound) resembles Pravastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin (Compound) resembles Simvastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Fludarabine |
DB00323 | DB00372 | 1,062 | 999 | [
"DDInter1829",
"DDInter1793"
] | Tolcapone | Thiethylperazine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
1062,
24,
999
]
],
[
[
1062,
24,
1614
],
[
1614,
63,
999
]
],
[
[
1062,
24,
1242
],
[
1242,
24,
999
]
],
[
[
1062,
63,
475
],
[
475,
... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone (Compound) resembles Entacapone (Compound) and Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin and Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine |
DB01208 | DB01362 | 945 | 497 | [
"DDInter1705",
"DDInter960"
] | Sparfloxacin | Iohexol | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
945,
25,
497
]
],
[
[
945,
21,
28681
],
[
28681,
60,
497
]
],
[
[
945,
64,
891
],
[
891,
25,
497
]
],
[
[
945,
40,
246
],
[
246,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caus... | Sparfloxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Sparfloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Iohexol
Sparfloxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Sparfloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iodixanol (Compound) and Iodixanol (Compound) resembles Iohexol (Compound) |
DB09381 | DB14723 | 192 | 159 | [
"DDInter678",
"DDInter1026"
] | Esterified estrogens | Larotrectinib | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
192,
24,
159
]
],
[
[
192,
63,
98
],
[
98,
24,
159
]
],
[
[
192,
24,
1320
],
[
1320,
24,
159
]
],
[
[
192,
62,
752
],
[
752,
24,... | [
[
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Soma... | Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Esterified estrogens may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB00196 | DB00261 | 600 | 702 | [
"DDInter743",
"DDInter93"
] | Fluconazole | Anagrelide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Major | 2 | [
[
[
600,
25,
702
]
],
[
[
600,
18,
6718
],
[
6718,
57,
702
]
],
[
[
600,
21,
29122
],
[
29122,
60,
702
]
],
[
[
600,
23,
112
],
[
112,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Fluconazole",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)"... | Fluconazole (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Anagrelide (Compound)
Fluconazole (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Anagrelide (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Anagrelide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Fluconazole may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Fluconazole may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol may lead to a major life threatening interaction when taken with Anagrelide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Anagrelide
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Anagrelide |
DB00526 | DB05679 | 1,555 | 1,683 | [
"DDInter1355",
"DDInter1907"
] | Oxaliplatin | Ustekinumab | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
1555,
24,
1683
]
],
[
[
1555,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
1555,
25,
1401
],
[
1401,
24,
1683
]
],
[
[
1555,
24,
1362
],
[
13... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Oxaliplatin may lead to a major life threatening interaction when taken with Procainamide and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Oxaliplatin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Ustekinumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Ustekinumab |
DB00019 | DB06176 | 1,257 | 1,342 | [
"DDInter1405",
"DDInter1616"
] | Pegfilgrastim | Romidepsin | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1257,
24,
1342
]
],
[
[
1257,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
1257,
24,
51
],
[
51,
24,
1342
]
],
[
[
1257,
24,
985
],
[
985,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Romidepsin
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin |
DB00570 | DB00673 | 147 | 723 | [
"DDInter1936",
"DDInter112"
] | Vinblastine | Aprepitant | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Moderate | 1 | [
[
[
147,
24,
723
]
],
[
[
147,
24,
875
],
[
875,
40,
723
]
],
[
[
147,
6,
8374
],
[
8374,
45,
723
]
],
[
[
147,
5,
11579
],
[
11579,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Vinblastine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is palliated by Aprepitant (Compound)
Vinblastine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal and Ulipristal may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Vinblastine may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant |
DB01236 | DB09080 | 679 | 144 | [
"DDInter1664",
"DDInter1331"
] | Sevoflurane | Olodaterol | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
679,
24,
144
]
],
[
[
679,
25,
1011
],
[
1011,
24,
144
]
],
[
[
679,
64,
11
],
[
11,
24,
144
]
],
[
[
679,
1,
1262
],
[
1262,
24... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolim... | Sevoflurane may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane (Compound) resembles Perflutren (Compound) and Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sevoflurane may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Olodaterol
Sevoflurane may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol |
DB08873 | DB11967 | 74 | 710 | [
"DDInter221",
"DDInter210"
] | Boceprevir | Binimetinib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
74,
24,
710
]
],
[
[
74,
64,
1593
],
[
1593,
24,
710
]
],
[
[
74,
25,
951
],
[
951,
24,
710
]
],
[
[
74,
63,
883
],
[
883,
24,
... | [
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotini... | Boceprevir may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Boceprevir may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Boceprevir may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Binimetinib |
DB00373 | DB09082 | 461 | 659 | [
"DDInter1809",
"DDInter1934"
] | Timolol | Vilanterol | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Major | 2 | [
[
[
461,
25,
659
]
],
[
[
461,
24,
1220
],
[
1220,
23,
659
]
],
[
[
461,
24,
1296
],
[
1296,
63,
659
]
],
[
[
461,
24,
1450
],
[
1450,
... | [
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Timolol may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Timolol may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may lead to a major life threatening interaction when taken with Vilanterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB00321 | DB09039 | 21 | 1,670 | [
"DDInter78",
"DDInter629"
] | Amitriptyline | Eliglustat | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Moderate | 1 | [
[
[
21,
24,
1670
]
],
[
[
21,
24,
121
],
[
121,
24,
1670
]
],
[
[
21,
40,
1164
],
[
1164,
24,
1670
]
],
[
[
21,
25,
478
],
[
478,
24... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline (Compound) resembles Promethazine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may lead to a major life threatening interaction when taken with Eliglustat
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib and Dacomitinib may lead to a major life threatening interaction when taken with Eliglustat |
DB00182 | DB08938 | 80 | 1,384 | [
"DDInter84",
"DDInter1112"
] | Amphetamine | Magaldrate | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976. During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
80,
24,
1384
]
],
[
[
80,
24,
401
],
[
401,
23,
1384
]
],
[
[
80,
40,
1529
],
[
1529,
24,
1384
]
],
[
[
80,
24,
478
],
[
478,
24... | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine (Compound) resembles Labetalol (Compound) and Labetalol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Amphetamine (Compound) causes Affect lability (Side Effect) and Affect lability (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00366 | DB00543 | 1,594 | 87 | [
"DDInter600",
"DDInter82"
] | Doxylamine | Amoxapine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. | Moderate | 1 | [
[
[
1594,
24,
87
]
],
[
[
1594,
24,
1119
],
[
1119,
1,
87
]
],
[
[
1594,
63,
905
],
[
905,
40,
87
]
],
[
[
1594,
63,
1174
],
[
1174,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Amoxapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Amoxapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Doxylamine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Amoxapine (Compound)
Doxylamine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Amoxapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine |
DB11248 | DB11988 | 1,193 | 270 | [
"DDInter1965",
"DDInter1321"
] | Zinc gluconate | Ocrelizumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia,,,. Studies show that zinc may be better absorbed in humans in the gluconate form,, however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrhe | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Minor | 0 | [
[
[
1193,
23,
270
]
],
[
[
1193,
23,
1019
],
[
1019,
24,
270
]
],
[
[
1193,
62,
1309
],
[
1309,
24,
270
]
],
[
[
1193,
23,
398
],
[
398,
... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
],
... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Basiliximab and Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab and Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort and Deflazacort may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Basiliximab and Basiliximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab |
DB05239 | DB09122 | 866 | 1,613 | [
"DDInter425",
"DDInter1409"
] | Cobimetinib | Peginterferon beta-1a | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
866,
24,
1613
]
],
[
[
866,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
866,
64,
152
],
[
152,
24,
1613
]
],
[
[
866,
25,
1155
],
[
1155,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may lead to a major life threatening interaction when taken with Bosentan and Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cobimetinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Cobimetinib may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Peginterferon beta-1a |
DB01075 | DB01089 | 1,376 | 1,340 | [
"DDInter569",
"DDInter502"
] | Diphenhydramine | Deserpidine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
1376,
24,
1340
]
],
[
[
1376,
63,
1245
],
[
1245,
40,
1340
]
],
[
[
1376,
35,
1264
],
[
1264,
63,
1340
]
],
[
[
1376,
24,
849
],
[
849... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
]... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Yohimbine (Compound) and Yohimbine (Compound) resembles Deserpidine (Compound)
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Yohimbine and Yohimbine (Compound) resembles Deserpidine (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound) |
DB00850 | DB09272 | 1,630 | 412 | [
"DDInter1432",
"DDInter632"
] | Perphenazine | Eluxadoline | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
1630,
24,
412
]
],
[
[
1630,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1630,
24,
830
],
[
830,
24,
412
]
],
[
[
1630,
1,
252
],
[
252,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine (Compound) resembles Hydroxyzine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Eluxadoline
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline |
DB09280 | DB12941 | 1,604 | 466 | [
"DDInter1101",
"DDInter481"
] | Lumacaftor | Darolutamide | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lum | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Major | 2 | [
[
[
1604,
25,
466
]
],
[
[
1604,
64,
336
],
[
336,
23,
466
]
],
[
[
1604,
25,
484
],
[
484,
23,
466
]
],
[
[
1604,
25,
159
],
[
159,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u}... | Lumacaftor may lead to a major life threatening interaction when taken with Nifedipine and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide
Lumacaftor may lead to a major life threatening interaction when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide |
DB08865 | DB11853 | 1,593 | 230 | [
"DDInter448",
"DDInter1577"
] | Crizotinib | Relugolix | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. | Major | 2 | [
[
[
1593,
25,
230
]
],
[
[
1593,
25,
129
],
[
129,
23,
230
]
],
[
[
1593,
24,
1094
],
[
1094,
23,
230
]
],
[
[
1593,
63,
112
],
[
112,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u... | Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a minor interaction that can limit clinical effects when taken with Relugolix
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix
Crizotinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Crizotinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Crizotinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix |
DB01018 | DB01254 | 1,364 | 1,213 | [
"DDInter847",
"DDInter484"
] | Guanfacine | Dasatinib | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
1364,
24,
1213
]
],
[
[
1364,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1364,
6,
10811
],
[
10811,
46,
1213
]
],
[
[
1364,
21,
28956
],
[
2... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Guanfacine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Guanfacine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Guanfacine (Compound) binds NISCH (Gene) and NISCH (Gene) is upregulated by Dasatinib (Compound)
Guanfacine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Guanfacine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Guanfacine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Dasatinib |
DB00486 | DB00844 | 1,614 | 314 | [
"DDInter1253",
"DDInter1257"
] | Nabilone | Nalbuphine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
1614,
24,
314
]
],
[
[
1614,
24,
828
],
[
828,
40,
314
]
],
[
[
1614,
63,
421
],
[
421,
1,
314
]
],
[
[
1614,
63,
475
],
[
475,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Nalbuphine
Nabilone (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Nalbuphine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Nalbuphine |
DB00188 | DB09280 | 168 | 1,604 | [
"DDInter222",
"DDInter1101"
] | Bortezomib | Lumacaftor | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms.[FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%.[A20343, L936] A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. | Major | 2 | [
[
[
168,
25,
1604
]
],
[
[
168,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
168,
24,
671
],
[
671,
24,
1604
]
],
[
[
168,
23,
837
],
[
837,
... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"En... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Lumacaftor
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Lumacaftor
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may lead to a major life threatening interaction when taken with Lumacaftor
Bortezomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Lumacaftor
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Lumacaftor
Bortezomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Lumacaftor |
DB00087 | DB00570 | 599 | 147 | [
"DDInter41",
"DDInter1936"
] | Alemtuzumab | Vinblastine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
599,
24,
147
]
],
[
[
599,
24,
134
],
[
134,
24,
147
]
],
[
[
599,
24,
970
],
[
970,
23,
147
]
],
[
[
599,
24,
37
],
[
37,
62,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Alemtuzumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Vinblastine
Alemtuzumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Vinblastine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Vinblastine |
DB00595 | DB11093 | 1,545 | 636 | [
"DDInter1374",
"DDInter273"
] | Oxytetracycline | Calcium citrate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1545,
24,
636
]
],
[
[
1545,
40,
1572
],
[
1572,
24,
636
]
],
[
[
1545,
23,
504
],
[
504,
24,
636
]
],
[
[
1545,
62,
811
],
[
811,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"... | Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate
Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate |
DB11003 | DB14762 | 748 | 994 | [
"DDInter100",
"DDInter1602"
] | Anthrax vaccine | Risankizumab | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis. | Moderate | 1 | [
[
[
748,
24,
994
]
],
[
[
748,
63,
4
],
[
4,
24,
994
]
],
[
[
748,
24,
270
],
[
270,
24,
994
]
],
[
[
748,
24,
676
],
[
676,
64,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mep... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab |
DB00661 | DB01240 | 122 | 885 | [
"DDInter1928",
"DDInter657"
] | Verapamil | Epoprostenol | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
122,
24,
885
]
],
[
[
122,
63,
1061
],
[
1061,
1,
885
]
],
[
[
122,
6,
6017
],
[
6017,
45,
885
]
],
[
[
122,
21,
28684
],
[
28684,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Verapamil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Verapamil (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Verapamil may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Verapamil may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol |
DB00356 | DB00792 | 1,315 | 832 | [
"DDInter366",
"DDInter1878"
] | Chlorzoxazone | Tripelennamine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1315,
24,
832
]
],
[
[
1315,
24,
100
],
[
100,
63,
832
]
],
[
[
1315,
24,
649
],
[
649,
1,
832
]
],
[
[
1315,
24,
1594
],
[
1594,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tripelennamine (Compound)
Chlorzoxazone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Tripelennamine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Tripelennamine (Compound) |
DB00468 | DB11718 | 1,424 | 927 | [
"DDInter1557",
"DDInter640"
] | Quinine | Encorafenib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
1424,
24,
927
]
],
[
[
1424,
23,
112
],
[
112,
23,
927
]
],
[
[
1424,
24,
720
],
[
720,
24,
927
]
],
[
[
1424,
63,
536
],
[
536,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may lead to a major life threatening interaction when taken with Relugolix and Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Quinine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Encorafenib |
DB06414 | DB11979 | 655 | 1,320 | [
"DDInter703",
"DDInter625"
] | Etravirine | Elagolix | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV- | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
655,
24,
1320
]
],
[
[
655,
62,
168
],
[
168,
23,
1320
]
],
[
[
655,
63,
608
],
[
608,
23,
1320
]
],
[
[
655,
24,
1297
],
[
1297,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Etravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Etravirine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etravirine may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix |
DB00372 | DB11732 | 999 | 1,097 | [
"DDInter1793",
"DDInter1027"
] | Thiethylperazine | Lasmiditan | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing cardiovascular disorders. Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically implicated in their vasoconstrictive activity.[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for the adverse effect profile of its predecessors - in other words, lasmiditan’s selectivity allows for the successful termination of migraines without causing vasoconstriction.[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class of anti-migraine medications in which lasmiditan is the first and only member: the neurally-acting anti-migraine medications (NAAMAs).[A187322,A187307] | Moderate | 1 | [
[
[
999,
24,
1097
]
],
[
[
999,
63,
701
],
[
701,
24,
1097
]
],
[
[
999,
24,
1614
],
[
1614,
24,
1097
]
],
[
[
999,
25,
1311
],
[
1311,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan |
DB00261 | DB13139 | 702 | 1,032 | [
"DDInter93",
"DDInter1063"
] | Anagrelide | Levosalbutamol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). | Moderate | 1 | [
[
[
702,
24,
1032
]
],
[
[
702,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
702,
24,
121
],
[
121,
24,
1032
]
],
[
[
702,
25,
982
],
[
982,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabo... | Anagrelide may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Anagrelide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol |
DB08871 | DB10343 | 36 | 962 | [
"DDInter666",
"DDInter160"
] | Eribulin | Bacillus calmette-guerin substrain tice live antigen | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
36,
25,
962
]
],
[
[
36,
64,
1057
],
[
1057,
25,
962
]
],
[
[
36,
63,
1342
],
[
1342,
25,
962
]
],
[
[
36,
24,
270
],
[
270,
64,... | [
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
... | Eribulin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen |
DB00704 | DB06589 | 267 | 1,250 | [
"DDInter1263",
"DDInter1400"
] | Naltrexone | Pazopanib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
267,
24,
1250
]
],
[
[
267,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
267,
18,
20113
],
[
20113,
46,
1250
]
],
[
[
267,
21,
29264
],
[
2926... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Naltrexone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Naltrexone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Pazopanib (Compound)
Naltrexone (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Naltrexone may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.